RNS Number : 9075L
Pharma C Investments PLC
08 September 2023

8 September 2023

Notice of General Meeting

Pharma C Investments Plc ("**Pharma C**" or the "**Company**") announces that, further to the announcement of 23 August 2023, a general meeting of the Company ("GM") will be held at 10am on Wed 27 September 2023 at the offices of Hill Dickinson LLP. Notice will shortly be posted to shareholders and will be available on the Company's website.

The GM was requisitioned by Paul Ryan, a shareholder holding more than 5% of the issued share capital of the Company to consider the following resolutions:

1. THAT Gavin Hilary Sathianathan be removed as a director of the Company with immediate effect

2. THAT Paul Ryan be appointed as a director of the Company

3. THAT Noel Lyons be appointed as a director of the Company

The Board recommends that shareholders vote against all the resolutions and has set out the reasons for this in the shareholder circular.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

The Directors of Pharma C accept responsibility for this announcement.

END

For additional information please contact:

Pharma C Investments

Gavin Sathianathan, Investment Strategy Director

gavin@pharmacinvestments.com

Novum Securities (AQSE Corporate Adviser)

Tel: +44 207 399 9400

David Coffman

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXBXGDCBUGDGXI